Overview
Current Appointments & Affiliations
Professor of Medicine
·
2018 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2004 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.
Journal Article J Clin Oncol · March 10, 2026 PURPOSE: Translational Breast Cancer Research Consortium 048 was a proof-of-principle trial demonstrating responses to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in patients (pts) with metastatic breast cancer (MBC) with germline (g) PALB2 ... Full text Link to item CiteReceipt of guideline-concordant local and chemotherapy-based systemic therapy for patients with triple-negative breast cancer: 10-year survival outcomes in a multi-state population-based analysis.
Journal Article Cancer · February 2026 BackgroundWomen diagnosed with triple-negative (ER-, PR-, HER2-) breast cancer (TNBC) have poor survival outcomes compared with other breast cancer subtypes. Yet there is little nonexperimental data on whether guideline-concordant therapy translat ... Full text CiteExamining the Interrelationships of Lymphedema with Pain, Physical Function, and Demographic and Medical Variables in Women with Breast Cancer and Pain.
Journal Article Clin Breast Cancer · January 2026 PURPOSE: To examine the relationship of lymphedema with pain, physical function, and demographic and medical variables in women with breast cancer and pain. METHODS: Secondary analysis of baseline data from a study of women with breast cancer and pain. Sel ... Full text Link to item CiteRecent Grants
Randomized Trial of a Targeted Palliative Care Intervention for Patients with Metastatic Breast Cancer (TARGET PC)
ResearchCo Investigator · Awarded by Massachusetts General Hospital · 2025 - 2030A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2023 - 2028Web-based Pain Coping Skills Training to Improve Pain and Poor Adherence caused by Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors (SKIP-Arthralgia): A Randomized Controlled Trial
ResearchCo Investigator · Awarded by Northwestern University · 2022 - 2027View All Grants
Education, Training & Certifications
Wake Forest University ·
2000
M.S.
Wake Forest University ·
1989
M.D.